AAV Contract Development and Manufacturing Organizations Market Report 2024 | Forecast by 2032

The global AAV contract development and manufacturing organizations market size reached US$ 675.1 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,500.3 Million by 2032,

Global AAV Contract Development and Manufacturing Organizations Market Statistics: USD 2,500.3 Million Value by 2032

Summary:

  • The global AAV contract development and manufacturing organizations market size reached USD 675.1 Million in 2023.

  • The market is expected to reach USD 2,500.3 Million by 2032, exhibiting a growth rate (CAGR) of 15.66% during 2024-2032.

  • North America leads the market, accounting for the largest AAV contract development and manufacturing organizations market share.

  • Downstream processing accounts for the majority of the market share in the workflow segment due to the high cost and technical expertise required for effective downstream processing.

  • Adherent culture holds the largest share in the AAV contract development and manufacturing organizations industry.

  • Cell and gene therapy development remain a dominant segment in the market owing to substantial investments and advancements in gene therapy research and development (R&D) activities.

  • Pharmaceutical and biopharmaceutical companies represent the leading end user segment.

  • The rising demand for gene therapy is a primary driver of the AAV contract development and manufacturing organizations market.

  • Technological advancements and increasing research and development (R&D) investments are reshaping the AAV contract development and manufacturing organizations market.

Industry Trends and Drivers:

  • Growing demand for gene therapy:

Gene therapies, which could replace or alter a faulty gene with a healthy gene are starting to appear more frequently. AAV vectors are preferred in these therapies because of the safety that comes with them and their efficiency when it comes to delivering therapeutic genes. Since more gene therapies are being worked on and approved, companies offering AAV manufacturing services are on high demand. However, the application of gene therapies to a clinical setting means that very high volumes of AAV vectors are needed. When gene therapies move from preclinical and phase I clinical trials to phase II and III clinical trials and finally toward the commercial scale, the/pandemonium pertaining to AAV production is eminent. The need for large scale manufacturing to support preclinical and clinical trials and later on for the commercialization of advanced gene therapies necessitates CDMOs with the capability to produce AAV vectors.

  • Increased R&D investment:

Growing levels of investment into gene therapy research results in the existence of more research activities being devoted to work on new therapies and applications. These projects require AAV vectors since they are effective and safe. Fostering this increased research activity, it drives the need for advanced AAV manufacturing offerings from contract development and manufacturing organizations. High R&D investment, therefore, seems to result in increased numbers of gene therapy products in early development. For these trials, a significant number of AAV vectors is required to bring the therapeutic approach to the human subjects. These vectors depend heavily on CDMOs, and this has seen companies working on AAV experience a boost in business.

  • Technological advancements:

Changes in the genetic universe and new technologies in vector design enable the development of improved AAV vectors. Optimization of vector design can be considered as one of the most prospective approaches to increasing transfection efficacy, decreasing immunogenicity, and achieving better outcome of the therapeutic intervention. Undoubtedly, CDMOs that remain abreast with the technological advancements are more likely to provide solutions that are technological a factor that attracts clients. Advent technologies in production methods like high-yield cell lines, a better procedure for fermentation, and other improved production procedures have helped improve AAV manufacturing efficiency.

Request for a sample copy of this report: https://www.imarcgroup.com/aav-contract-development-manufacturing-organizations-market/requestsample

AAV Contract Development and Manufacturing Organizations Market Report Segmentation:

Breakup By Workflow:

  • Upstream Processing

  • Downstream Processing

Downstream processing represents the largest segment due to the complexity and importance of ensuring high-quality and contamination-free products.

Breakup By Culture Type:

  • Adherent Culture

  • Suspension Culture

Adherent culture accounts for the majority of the market share owing to their established processes for high-density cell growth and efficient vector production, leading to their majority market share.

Breakup By Application:

  • Cell and Gene Therapy Development

  • Vaccine Development

  • Biopharmaceutical and Pharmaceutical Discovery

  • Biomedical Research

Cell and gene therapy development exhibits a clear dominance in the market because of their central role in innovative treatments for genetic disorders, resulting in their dominance in the market.

Breakup By End User:

  • Pharmaceutical and Biopharmaceutical Companies

  • Academic and Research Institutes

Pharmaceutical and biopharmaceutical companies hold the biggest market share, driven by their extensive investment in gene therapies and need for large-scale, reliable vector production.

Breakup By Region:

  • North America (United States, Canada)

  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

  • Latin America (Brazil, Mexico, Others)

  • Middle East and Africa

North America enjoys the leading position in the AAV contract development and manufacturing organizations market on account of its advanced biotechnology infrastructure, significant R&D investments, and high demand for innovative gene therapies.

Top AAV Contract Development and Manufacturing Organizations Market Leaders:

The AAV contract development and manufacturing organizations market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

  • ABL Manufacturing (Institut Mérieux)

  • Asklepios BioPharmaceutical Inc. (Bayer AG)

  • Anlongbio

  • Belief Biome Inc.

  • Catalent Inc.

  • Charles River Laboratories International Inc.

  • Creative Biogene

  • GenScript ProBio (GenScript Biotech Corporation)

  • Merck KGaA

  • Oxford Biomedica

  • TFBS Bioscience Inc.

  • Thermo Fischer Scientific Inc.

Note: If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145

Last updated